Skip to content

Preferred Stock at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$0
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$0
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$0
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$0
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$0
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$0

Other financials

Income statement

See full
Revenue-
Operating income-$53.7M+2.4%
Net income-$49.7M-2.4%
EPS (diluted)-$0.69+24.2%

Balance sheet

See full
Cash & equivalents$75.1M-2.1%
Total debt$2.4M+29.5%
Total equity$408.7M-30.8%
Total assets$403.0M-30.5%

Cash flow

See full
Operating cash flow-$46.0M-6.7%
CapEx$11.0K
Free cash flow-$38.1M-4.1%

Valuation

See full
Market cap$1.08B+94.2%
Enterprise value$1.01B+114%

Profitability

See full
Operating margin-358.7%
Net margin-346.1%

Returns & leverage

See full
Return on equity-44%+26.2pp
Debt / equity0.0×
Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s preferred stock?
Cullinan Therapeutics, Inc. (CGEM) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.